Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial

Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial

Abstract Background The JACOB trial (NCT01774786) was a double-blinded, placebo-controlled, randomized, multicenter, international, phase III trial evaluating the efficacy and safety of adding pertuzumab to trastuzumab and chemotherapy in first-line treatment of human epidermal growth factor recepto...

Full description

Bibliographic Details
Main Authors: Tianshu Liu, Yanru Qin, Jin Li, Ruihua Xu, Jianming Xu, Shujun Yang, Shukui Qin, Yuxian Bai, Changping Wu, Yixiang Mao, Haiyan Wu, Yilin Ge, Lin Shen
Format: Article
Language:English
Published: Wiley 2019-06-01
Series:Cancer Communications
Subjects:
Gastric cancer
Gastroesophageal junction cancer
HER2
Pertuzumab
Trastuzumab
Chemotherapy
Online Access:http://link.springer.com/article/10.1186/s40880-019-0384-6

Internet

http://link.springer.com/article/10.1186/s40880-019-0384-6

Similar Items